Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ.
Location: United States, Massachusetts, Norwood
Employees: 51-200
Phone: +1 617-963-0100
Total raised: $25M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.01.2018 | - | $25M | - |
Mentions in press and media 8
| Date | Title | Description |
| 12.03.2024 | Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | - |
| 06.03.2024 | Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit | - |
| 12.11.2021 | Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates | NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for t... |
| 24.08.2020 | CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals : Conference Call Transcript Q3 2018 | Corbus Pharmaceuticals Holdings, Inc. Quarterly Update Conference Call and Webcast November 8, 2018 Operator: Greetings and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all participants a... |
| 13.08.2020 | CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals : Conference Call Transcript Q2 2020 | Corbus Pharmaceuticals Holdings Second Quarter Earnings Conference Call August 6, 2020 Page 1 of 14 Operator: Hello and welcome to the Corbus Pharmaceuticals Second Quarter August 6, 2020 Earnings Conference Call. As a reminder, all partici... |
| 26.07.2019 | Peer Review: Rubius recruits BD chief; Epizyme hires Novartis vet as CFO | Kris Elverum → Rubius Therapeutics — clinical-stage biopharmaceutical company developing a new class of medicines called red cell therapeutics — made the addition of Kris Elverum to its senior leadership team as SV... |
| 30.01.2018 | Corbus scores $25M from Cystic Fibrosis Foundation for 415-patient study | Corbus Pharmaceuticals has bagged $25 million from the Cystic Fibrosis Foundation, which will carry its cystic fibrosis drug, lenabasum, through a 415-patient phase 2b trial. The development award comes in a new venture philanthropy model f... |
| 27.10.2017 | Biotech Peer Review: Magenta onboards five new VPs; BioInvent is hunting for a new CEO | → Following a $50 million series B in April, stem cell transplantation startup Magenta Therapeutics is filling some key roles in its leadership team. The company is taking on four new vice presidents and a senior vice ... |